Share

Pfizer abandons plan to split into two companies

New York - US drug maker Pfizer, which has been considering a split into two companies for more than two years, said on Monday it will not do so because the move would not create any shareholder value.

Pfizer will keep its low-growth generics and patent-protected branded medicines separate, giving it the option to split down the road if "factors materially change at some point in the future."

Pfizer said on Monday the decision would not have an impact on its 2016 financial forecast.

The decision not to create two publicly traded companies follows the collapse of its planned $160bn acquisition of Allergan after a change in tax law took away the tax benefits of the deal.

Investors were expecting the company to step back from the split, Sanford Bernstein analyst Tim Anderson said in a research note.

"Where to from here? The company seems likely to leave open its option for a future split-up, but more immediately it may continue hunting for M&A targets," Anderson wrote.

Pfizer's shares were down 1.2% to $33.85 in premarket trading on Monday.

The pharma giant began openly planning for the possible split in early 2014, saying it would operate the businesses as separate divisions and track their progress for three years before reaching a decision.

In August, it said a decision would be made by year-end.

Pfizer said the sum-of-the-parts analysis showed no benefit to shareholders, and that tax costs and business disruptions were factors it considered.

The company had considered the move largely because its patent-protected medicines routinely enjoy sales growth while sales in the generics portfolio usually declined.

Investors shifted their focus to whether Pfizer would split after the company terminated the deal for Irish drug maker Allergan in April.

In August Pfizer announced it was buying cancer drug maker Medivation for $14bn to get access to blockbuster prostate cancer drug Xtandi for its growing oncology roster.

The Medivation deal illustrates a shift in Pfizer's mergers and acquisitions strategy from lowering taxes, which was the rationale behind the failed Allergan tax inversion deal, to strengthening its line-up of branded drugs, especially lucrative cancer treatments.

A year ago, Pfizer paid $15bn for Hospira, which sells generic hospital products and is developing biosimilars to compete with big-selling injectable biotech drugs.

That deal was seen by Wall Street as a way of bolstering its generic drugs operation ahead of potentially divesting the business.

Read Fin24's top stories trending on Twitter:

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Rand - Dollar
19.00
-0.5%
Rand - Pound
24.02
-0.5%
Rand - Euro
20.53
-0.3%
Rand - Aus dollar
12.37
-0.2%
Rand - Yen
0.13
-0.6%
Platinum
904.37
+0.8%
Palladium
1,014.65
+1.3%
Gold
2,205.79
+0.5%
Silver
24.61
-0.1%
Brent Crude
86.09
-0.2%
Top 40
68,281
+0.9%
All Share
74,458
+0.7%
Resource 10
57,014
+2.4%
Industrial 25
103,960
+0.7%
Financial 15
16,486
-0.2%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders